1.Lamagni, T, et al. The epidemiology of severe Streptococcus pyogenes associated disease in Europe. Eurosurveillance 2005; 10: 179–184.
2.Rogers, S, et al. Strain prevalence, rather than innate virulence potential, is the major factor responsible for an increase in serious group a streptococcus infections. Journal of Infectious Diseases 2007; 195: 1625–1633.
3.Lopardo, H, et al. Six-month multicenter study on invasive infections due to Streptococcus pyogenes and Streptococcus dysgalactiae subsp. equisimilis in Argentina. Journal of Clinical Microbiology 2005; 43: 802–807.
4.Ikebe, T, et al. Surveillance of severe invasive group-G streptococcal infections and molecular typing of the isolates in Japan. Epidemiology and Infection 2004; 132: 145–149.
5.O'Brien, K, et al. Epidemiology of invasive group A streptococcus disease in the United States, 1995–1999. Clinical Infectious Diseases 2002; 35: 268–276.
6.Davies, H, et al. Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group. New England Journal of Medicine 1996; 335: 547–554.
7.Jasir, A, Schalen, C. Strep-EURO: progress in analysis and research into severe streptococcal disease in Europe, 2003–2004. Eurosurveillance 2005; 10: 179–184.
8.Carapetis, J, et al. The global burden of group A streptococcal diseases. Lancet Infectious Diseases 2005; 5: 685–694.
9.Berkley, J, et al. Bacteremia among children admitted to a rural hospital in Kenya. New England Journal of Medicine 2005; 352: 39–47.
10.Hoge, C, et al. The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome. A retrospective population-based study. Journal of the American Medical Association 1993; 269: 384–389.
11.Norton, R, et al. Invasive group A streptococcal disease in North Queensland (1996–2001). Indian Journal of Medical Research 2004; 119 (Suppl.): 148–151.
12.Holm, S. Invasive group A streptococcal infections. New England Journal of Medicine 1996; 335: 590–591.
13.Hashikawa, S, et al. Characterization of group C and G streptococcal strains that cause streptococcal toxic shock syndrome. Journal of Clinical Microbiology 2004; 42: 186–192.
14.Li, Z, et al. Array of protein gene subtypes in 1064 recent invasive group A streptococcus isolates recovered from the Active Bacterial Core Surveillance. Clinical Infectious Diseases 2003; 188: 1587–1592.
15.Carapetis, J, et al. Clinical and epidemiological features of group A streptococcal bacteraemia in a region with hyperendemic superficial streptococcal infection. Epidemiology and Infection 1999; 122: 59–65.
16.Chun, LT, et al. Acute rheumatic fever in Hawaii: 1966 to 1988. Hawaii Medical Journal 1992; 51: 206–211.
17.Lennon, D, et al. Longitudinal study of poststreptococcal disease in Auckland; rheumatic fever, glomerulonephritis, epidemiology and M typing 1981–86. New Zealand Medical Journal 1988; 101: 396–398.
18.United Nations Development Programme, 2006. In: Ross-Larson, B, Coqureaumont, MD, Trott, C eds. Human Development Report, 2006.
19.Ministry of Health Annual Report. Suva: Parliament of Fiji, 2005.
21.Hayman, W, et al. Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of the group A streptcoccus. International Immunology 1997; 9: 1723–1733.
22.Batzloff, M, et al. Protection against group a streptococcus by immunization with J8-diptheria toxoid: contribution of J8- and Diptheria toxoid-specific antibodies to protection. Journal of Infectious Diseases 2003; 187: 1598–1608.
23.Macgree, H, et al. Chest X-ray-confirmed pneumonia in children in Fiji. Bulletin of the World Health Organisation 2005; 83: 427–433.
24.Fiji Bureau of Statistics. Key Statistics September 2006. In: Statistics Fiji Bureau of Statistics. Suva, 2006.
25.Erdem, G, et al. Molecular epidemiologic comparison of 2 unusual clusters of group A streptococcal necrotizing fasciitis in Hawaii. Clinical Infectious Diseases 2005; 40: 1851–1854.
26.Sakota, V, et al. Genetically diverse group A streptococci from children in far-Western Nepal share high genetic relatedness with isolates from other countries. Journal of Clinical Microbiology 2006; 44: 2160–2166.
27.McNeil, S, et al. A double-blinded, randomized, controlled phase II trial of the safety and immunogenicity of a 26 valent group A streptococcus vaccine in healthy adults. The XVIth Lancefield International Symposium on Streptococci and Streptococcal Diseases, 25–29 September 2005; Palm Cove, Australia.